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Abstract 
Purpose: To investigate whether modified acidic fibroblast growth factor (MaFGF) can protect NRK52E 
cell against apoptotic death induced by actinomycin D (Act D) and the effect of MaFGF on PI3K/Akt 
signaling pathway.  
Methods: NRK52E cell apoptotic death was measured by several methods including cell morphologic 
observation, Hoechst 33342 staining and flow cytometry. In addition, the levels of phosphorylated-Akt 
protein were analyzed by Western blotting method.  
Results: The results showed that 0.75 mg/L Act D-treated NRK52E cell for 20 h was the optimal 
conditions for establishing NRK52E cell apoptotic model. Different doses of MaFGF (0.01, 0.03, 0.1, 0.3 
and 1.0 mg/L) decreased apoptotic rate but enhanced the expression of phosphorylated Akt protein. 
However, MaFGF’s protection against Act D-induced apoptosis was significantly (p < 0.05) prevented 
when NRK52E cells were exposed to wortmannin.  
Conclusion: These results reveal that MaFGF can reduce the level of ActD-induced apoptotic cell 
death in 20 h, and the protective mechanism of MaFGF may be associated with the activation of 
PI3K/Akt signaling pathway by up-regulation of expression of phosphorylated Akt protein. 
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Actinomycin D (Act D), as a transcriptional 
inhibitor, can inhibit protein synthesis. Recent 
studies have shown that Act D, at a 
concentration of 0.8 - 1.0 µg/ml or higher, causes 
typical apoptotic cell death in a variety of cell 
lines [1,2]. Consequently, Act D has been used 
for establishing cell apoptotic models.  
 
It has been reported that the mechanism of Act 
D-induced apoptotic death is closely related to 
PI3K/Akt signaling pathway, which includes PI-
3K, PKB/Akt and 70s6K [3]. The activation of Akt, 
known as protein kinase B (PKB), is an important 
prerequisite in PI3K/Akt signaling pathway, which 
involves a series of activities such as regulating 
cell apoptosis, proliferation, differentiation and 
metabolism. Andreucci et al suggested that PI3-
kinase/Akt signaling pathway plays an important 
role in the regulation of renal repair after 
ischemia/reperfusion injury [4]. Xie et al 
demonstrated that wortmannin, which is the 
special inhibitor of PI3K, may increase the levels 
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of serum creatinine and urea nitrogen, and 
enhance the degree of renal injury during kidney 
ischemia-reperfusion injury in mice; they also 
suggested that there was a relationship between 
PI3-kinase/Akt signaling and renal injury [5].  
 
Acidic fibroblast growth factor (aFGF) is one of 
the members of the FGFs family with many 
biological effects, such as promotion of cell 
proliferation, growth and differentiation. It has 
been proved that aFGF exhibits mitogenic and 
non-mitogenic activities, and its powerful 
mitogenic activities have been implicated in 
some pathological processes including 
hyperblastosis, tumorigenesis and metastasis 
[6,7]. It has previously been reported that an N-
terminal nuclear localization sequence (NLS) in 
aFGF is required for full mitogenic activity. 
Modification of the N-terminal of aFGF gene and 
elimination of N terminal residues 1–27 plus 
methionine substitution of leucine at the site of 
27 yields a human acidic fibroblast growth factor 
mutant (haFGF27-154), that is, modified aFGF 
(MaFGF) [8,9]. It has been shows that when the 
N-side 1 to 27 amino-acid residue of aFGF is 
removed, its mitogenic activity is lost or obviously 
decrease, but its non-mitogenic effect still exists 
[9-12].  
 
Our previous studies have demonstrated that 
MaFGF can prevent renal ischemia-reperfusion 
injury in rats [13]. Whether MaFGF has protective 
effect on renal tubular epithelial cells has not 
been reported. The present study was 
undertaken assess the effect of MaFGF on a 
normal rat kidney proximal tubule epithelial cell 
line (NRK52E) cell apoptosis induced by Act D, 
and also to study the effect of MaFGF on 






MaFGF was supplied by Biopharmaceutical 
Research and Development Center of Jinan 
University, China. Before use, it was diluted with 
high-glucose (4.5 g/L glucose) Dulbecco’s 
modified Eagles Medium (DMEM, Gibco, USA) to 
the required concentration. Act D and 
wortmannin were purchased from Sigma 
Chemical Co (St Louis, MO, USA). Specific 
antibodies for total Akt or phosphorylated Akt 
(Ser473) were purchased from Cell Signaling 
(Beverly, MA, USA) and Santa Cruz 
Biotechnology (Santa Cruz, CA, USA), 
respectively, while and Hoechst 33342 dye was 
purchased from Sigma Chemical Co (St Louis, 




NRK52E cell line, a normal rat kidney proximal 
tubule epithelium line, from the kidney disease 
Institution of Sun Yat-Sen Medical University, 
were cultivated at 37 °C in an atmosphere 
containing 5 % CO2, 95 % air and relative 
humidity of 98%. The culture medium high 
glucose (DMEM, Gibco, USA) contained 100 g/L 
fetal bovine serum (heat inactivated), 10 U/ml 
penicillin and 100 mg/ml streptomycin, and the 
cells were transferred to fresh culture medium 
every 2 - 3 days. 
 
Cell apoptosis assay 
 
Samples were prepared for flow cytometry as 
described previously.[14] Briefly, treated cells (5 
× 105/well)  were digested by 0.25 % trypsin, 
harvested and rinsed with PBS 3 times, fixed 
with 70 % ethanol at 4 0C overnight. The fixed 
cells were rinsed with PBS 3 times, treated with 
RNAse at 37 0C for 30 min, and then stained by 
propidium iodide (PI) at 4 0C for 30 min. Finally, 
apoptosis rates were detected with flow 
cytometry (FCA-SCalibur, Becton Dickinson, 
USA). 
 
Hoechst 33342 Staining 
 
Samples were prepared for Hoechst 33342 
staining as described previously [14]. Briefly, 
coverslips with adherent treated NRK52E cell 
were collected at specified time points and 
washed, and the cells were fixed with 4 % 
paraformaldehyde at 4 0C for 10 min and stained 
with Hoechst 33342 (5 µg/ml) for 20 min at room 
temperature in the dark. They were rinsed with 
PBS for 3 times, the cells were viewed with a 
fluorescence microscope equipped with a UV 
filter (Nikon, Tokyo, Japan). The images were 
recorded on a computer with a camera attached 
to the microscope. The Hoechst reagent was 
taken up by the nuclei of the cells and apoptotic 
cells exhibited a bright blue fluorescence.  
 
Western blot analysis 
 
Akt expression and phosphorylation were 
examined by Western blotting analysis according 
to previously published methods [15]. Briefly, 
protein 40 µg was spotted per lane and 
subjected to 12% SDS-PAGE and subsequently 
transferred to PVDF membrane. The membranes 
were blocked with 5% skimmed milk and 
sequentially incubated with phosphorylated Akt 
antibody or anti-Akt overnight at 4℃, followed by 
incubation with IgG-HRP conjugated secondary 
antibody (1:1000 dilution) at room temperature 
for 1.5 hrs and rinsed with TBST (TBS containing 
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0.1 % Tween 20, 3 × 10 min). The blots were 
detected by enhanced chemiluminescence (ECL) 
detection system (Amersham Pharmacia) s and 
the images were scanned by gel image analysis 
system. β-actin was used as a reference for 




Data were expressed as mean ± standard 
deviation (SD). Statistical analysis was 
performed using the SPSS software package 
(version 10.0, SPSS Company, USA). 
Differences between groups were assessed by 
one-way analysis of variance (ANOVA). P < 0.05 




Actinomycin D-induced NRK52E cell 
apoptosis 
 
The morphological change in Act D-induced 
NRK52E cell apoptosis is shown in Figure 1. In 
the control group, the cells looked like a 
cobblestone – irregular appearance and compact 
arrangement. For the 0.5 mg/L and 0.75 mg/L 
Act D groups, abnormal morphologic change of 
NRK52E cell observed. Some cellular nuclei 
condensed and broke into pieces and a few 
apoptotic bodies could be seen. Comparing the 
cell apoptotic results among all Act D-treated 
groups, 0.75 mg/L Act D treated for 20 h was a 
better process condition for inducing NRK52E 
cell apoptosis.  
 
The cell apoptotic rate detected by flow 
cytometry indicated that NPK52E cells apoptosis 
induced by Act D at concentration of 0.25 mg/L, 
0.5 mg/L, 0.75 was dose-dependent, and the 
concentration of 0.75 mg/L Act D was the optimal 
condition for inducing NPK52E cells apoptosis 
(Figure not shown). 
 
Protective effect of MaFGF against Act D-
induced NRK52E cell apoptosis 
 
The results showed that pre-treatment with 
MaFGF at doses of 0.01, 0.03, 0.1, 0.3, 1.0 mg/L 
significantly protected NRK52E cell against Act 









(d)  (e)   
Fig 1: Morphological changes in NRK52E cells exposed to Act D for 20 h (×200). (a) Normal NPK52E cells. (b) 
NRK52E cells exposed to 0.25 mg /L Act D. (c) NRK52E cells exposed to 0.5 mg /L Act D. (d) NRK52E cells 
exposed to 0.75 mg /L Act D. (e) NRK52E cells exposed to 1.0 mg /L Act D.  
 
Figure 2: Protective effect of MaFGF on apoptosis of NRK52E cells exposed to 0.75 mg/L Act D for 20 h. Data 
are presented as mean ± SD (n = 5); *p < 0.01 versus control group (no Act D); △p < 0.05, △△p < 0.01 versus 
model group (Act D alone) 
Xu et al 




       
       
Figure 3: Apoptotic cell death was detected with Hoechst 33342 staining by observation of the nuclear 
condensation (×200). (A) normal cells; (B) cells treated with 0.75 mg /L Act D for 20 h; (C) cells pretreated with 
0.1 mg/L MaFGF for 24 h and then treated with 0.75 mg /L Act D for 2 h; (D) cells pretreated with 200 nmol/L 
wortmannin for 2 h and then with 0.75 mg /L Act D for 20 h 
 
Figure 4: Influence of wortmannin on Act D-induced NRK52E cell apoptosis and on protection of MaFGF against 
Act D-induced NRK52E cell apoptosis. The apoptosis was measured by flow cytometry with PI staining. (W: 
Wortmannin; A: Act D; M: MaFGF). Data are presented as mean ± SD (n = 5).△△p < 0.01 versus control group, *p 
< 0.05, **p < 0.01 versus A group, ■p < 0.05 versus “W+A” group 
 
The anti-apoptostc effect of MaFGF at 0.1 mg/L 
on Act D-indued apoptisis was also confirmed by 
Hoechst 33342 staining (Figure 4C), showing a 
significant decrease (p < 0.05) of the number of 
cells with nuclear condensation in MaFGF 
combined with Act D groups, when compared to 
that in Act D only group (Figure 3B). 
 
Protective effect of MaFGF against Act D-
induced apoptosis is associated with 
activtion of PI-3K/Akt signaling pathway 
 
The results showed wortmannin did not increase 
cell apoptosis in control cells, but significantly (p 
<0.05), enhanced Act D-induced apoptosis, 
measured by flow cytometry (Figure 4). The 
enhanced effect of wortmannin on Act D-induced 
apoptosis was further confirmed by Hoechst 
33342 staining (Figure 3D), which showed that 
the number of nuclear condensed cells in Act D 
combined with wortmannin group increased, 
compared to the group of Act D alone (Figure 
3B). Pre-treatment with wortmannin could 
significantly block the protective effect of MaFGF 
against Act D-induced apoptosis (Figure 4). 
 
The results of Western-blotting analysis showed 
that of total Akt expression was not changed in 
various groups (data not shown) and 
phosphorylated Akt expression was significantly  
(p <0.05) increased in MaFGF-treated cells 
(Figure 5). The relative phosphorylated Akt 
quantification related to β actin shown that 
expressions of phosphorylated Akt in MaFGF 
groups at doses of 0.1, 0.3 and 1.0 mg/L 
significant increased compared to the model  
345 
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Fig 5: Effect of MaFGF on expression of phosphorylated Akt protein. Key: (for A and B): 1 = control group 
(control group); 2 = model group (0.75 mg/L Act D); 3 - 7 = MaFGF (0.01, 0.03, 0.1, 0.3 and 1.0 mg/L, 
respectively); β-actin was used as a reference for making quantitative comparison (A). The data is presented as 
mean ± SD (n = 5).△P<0.05,△△<0.01 versus model group; *P<0.05 versus control group (B)   
 
group. Thus, the effect of MaFGF on activated 
PI-3K/Akt signaling was related to up-regulation 




Renal tubular epithelial cell apoptosis has been 
suggested as the cause of kidney damage during 
renal ischemia-reperfusion, acute renal failure, 
drug poisoning and so on [16-18]. Therefore, 
protecting renal against injury and promoting 
renal repair after injury is a key treatment 
strategy in acute renal failure.  
 
MaFGF is a mutant of human acidic fibroblast 
growth factor, which also is called non-mitogenic 
human acidic fibroblast growth factor because its 
N-terminal is modified and its mitogenic activity is 
obviously lower than that of aFGF [9,11]. Recent 
findings have shown that MaFGF has a variety of 
anti-apoptosis effects, such as antagonizing 
ischemia/reperfusion-induced intestinal epithelial 
cell apoptosis, inhibiting CCl4-induced 
hepatocyte apoptosis, preventing H2O2-induced 
myocardial apoptosis, as well as resisting 
dexamethasone-induced thymocytes apoptosis 
[10,12,19,20].  However, whether MaFGF can 
protect NRK52E cell against apoptosis remains 
poorly understood.  
 
In present study, we used Act D to induce 
NRK52E cell apoptosis and to investigate 
whether MaFGF can protect NRK52E cell 
against Act D-induced apoptosis. Treatment of 
NRK52E cells with different doses and time 
showed that 0.75 mg/L Act D for 20 h was the 
optimal condition for establishing a apoptosis 
model with characteristics such as stability, dose-
reliability and ease of replication. The results 
demonstrate that MaFGF can protect NRK52E 
cell against Act D-induced NRK52E cell 
apoptosis in a dose-dependent manner.  
 
Previous studies have revealed that PI-3K/Akt 
signaling pathway plays a very important 
regulatory role in renal ischemia-reperfusion 
injury. Akt, a crucial cell survival signal 
transducer, can inhibit apoptosis through 
phosphorylation and inactivation of the 
proapoptotic proteins [1,21]. It has already been 
found that pre-treatment with PI-3K inhibitors 
wortmannin increases the degree of injury of 
renal tubule, indicating that there is a relationship 
between renal injury and PI-3K/Akt signaling 
pathway [22-24].   
 
We also investigated the relationship between 
the effect of MaFGF on NRK52E cell apoptosis 
and activation of PI3K/Akt signaling. The results 
demonstrate that the anti-apoptotic effect of 
MaFGF is associated with the activation of PI-
3K/Akt signaling pathway. This conclusion was 
based on the following: (1) when the cells were 
pre-treated with wortmannin, the anti-apoptotic 
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NRK52E cell with MaFGF for 24 h, Akt was 
hyperphosphorylated unlike the model group. 
These findings confirm that the protective effect 
of MaFGF against ActD was related to activation 
of PI-3K/Akt signaling because the anti-apoptosis 
ability of MaFGF was antagonized by 
wortmannin through inhibition of PI3K/Akt 
signaling, causing the cells to be more vulnerable 
to Act D damage. The increasing levels of 
phosphorylated Akt induced by MaFGF are 
consistent with the protective efficacy of MaFGF 
and thus further supports this conclusion.  
 
Remarkably, our results show that the level of 
phosphorylated Akt protein increased in Act D 
model unlike in the normal group, suggesting that 
PI-3K/Akt signaling was activated when NRK52E 
cells were injured by Act D, which acted as an 
initiator of injury; this may be as a result of the 
body's own anti-injury regulation. This finding is 
similar to that reported earlier where it was found 
that phosphorylated Akt (activated form) level 
increased after renal ischemia-reperfusion injury 
in mice [5]. The higher levels of phosphorylated 
Akt protein in MaFGF groups demonstrate that 
MaFGF further facilitates the activation of 




MaFGF can protect NRK52E cell against Act D-
induced apoptosis. This finding is consistent with 
our previous reports that MaFGF can antagonize 
H2O2-induced NRK52E cell apoptosis [25].  
Increase in phosphorylated Akt after treatment 
with MaFGF is linked to anti-apoptosis of 
MaFGF. Therefore, activation of PI3K/Akt 
signaling plays a key role in the protection of 
MaFGF on NRK52E cell. Associated with the 
anti-apoptotic effect of MaFGF on other cells as 
mentioned above, it can be inferred that the anti-
apoptotic effect of MaFGF on different cells have 
something in common. One of the anti-apoptotic 
mechanisms might be attributable to the 
activation of PI3K/Akt signaling pathway via 
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